Meta-Inflammation and New Anti-Diabetic Drugs: A New Chance to Knock Down Residual Cardiovascular Risk

Type 2 diabetes mellitus (DM) represents, with its macro and microvascular complications, one of the most critical healthcare issues for the next decades. Remarkably, in the context of regulatory approval trials, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: d’Aiello, Alessia, Bonanni, Alice, Vinci, Ramona, Pedicino, Daniela, Severino, Anna, De Vita, Antonio, Filomia, Simone, Brecciaroli, Mattia, Liuzzo, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217924/
https://www.ncbi.nlm.nih.gov/pubmed/37239990
http://dx.doi.org/10.3390/ijms24108643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217924/
https://www.ncbi.nlm.nih.gov/pubmed/37239990
http://dx.doi.org/10.3390/ijms24108643

Ejemplares similares